OPL-0401 for Diabetic Retinopathy
(Spectra Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called OPL-0401 to determine its safety and effectiveness for people with diabetic retinopathy, a condition where diabetes damages the eyes. Participants will receive either the OPL-0401 treatment or a placebo (a substance with no therapeutic effect) for 24 weeks. The trial seeks individuals with diabetes who have specific levels of eye damage but haven't recently undergone certain eye treatments or surgeries. This offers a chance to potentially improve eye health while contributing to research on diabetic retinopathy. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, it mentions that your diabetes and blood pressure should be controlled, which might require continuing your current treatments.
Is there any evidence suggesting that OPL-0401 is likely to be safe for humans?
Research has shown that OPL-0401 is generally safe and well-tolerated by users. In earlier studies, certain doses appeared to help prevent diabetic retinopathy, an eye condition related to diabetes. Although exact details on side effects are not available, its continued testing indicates that its safety is deemed sufficient for further research.12345
Why do researchers think this study treatment might be promising for diabetic retinopathy?
Researchers are excited about OPL-0401 for diabetic retinopathy because it offers a potential new approach to treating this eye condition. Most current treatments involve injections into the eye or laser surgery, which can be invasive and uncomfortable. OPL-0401 is unique as it is taken orally, making it a non-invasive option. Additionally, this treatment may work by targeting specific pathways involved in the disease, which could lead to better outcomes for patients with fewer side effects.
What evidence suggests that OPL-0401 might be an effective treatment for diabetic retinopathy?
In this trial, participants will receive either OPL-0401 or a placebo. Research suggests that OPL-0401 might slow the progression of diabetic retinopathy, an eye problem caused by diabetes. However, one study found that OPL-0401 did not significantly improve the condition compared to a placebo, which contains no active drug. While there are some hopeful signs, the treatment hasn't consistently shown effectiveness. The drug targets a specific process involved in diabetic retinopathy. Overall, results are mixed, with some early signs of potential but no strong proof of effectiveness.12346
Who Is on the Research Team?
Victor Shi, M.D.
Principal Investigator
Valo Health, Inc.
Are You a Good Fit for This Trial?
This trial is for adults over 18 with diabetic retinopathy, a condition affecting the retina due to diabetes. Participants can have mild vision impairment but must not be extremely overweight or have uncontrolled diabetes or blood pressure. They shouldn't need other eye treatments for 6 months and haven't had recent eye surgery or certain past treatments like laser photocoagulation.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive OPL-0401 or placebo twice daily for 24 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- OPL-0401
- Placebo
Trial Overview
The study tests OPL-0401's safety and effectiveness in treating diabetic retinopathy compared to a placebo. It's given to people with varying severity of this eye disease, who are then monitored to see if their condition improves without requiring additional procedures.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Participants are randomized to OPL-0401 Dose 1 twice daily for 24 weeks
Participants are randomized to matching Placebo twice daily for 24 weeks
Find a Clinic Near You
Who Is Running the Clinical Trial?
Valo Health, Inc.
Lead Sponsor
Citations
1.
valohealth.com
valohealth.com/press/valo-health-announces-topline-results-from-phase-2-spectra-study-of-opl-0401-in-patients-with-diabetic-retinopathyValo Health Announces Topline Results from Phase 2 ...
OPL-0401 demonstrated favorable safety profile and certain doses tested indicate promise in preventing disease progression.
Phase 2 Spectra Study to Evaluate the Safety and Efficacy ...
OPL-0401-201 is a multicenter study to investigate the safety and efficacy of OPL-0401 in patients with diabetes mellitus (DM) with diabetic retinopathy.
Flagship's computationally driven AI startup hits setback in ...
Topline data demonstrated that OPL-0401 failed to achieve a statistically significant improvement in DR severity score compared with placebo, ...
4.
ophthalmologymanagement.com
ophthalmologymanagement.com/news/2025/valo-health-suspends-development-of-diabetic-retinopathy-drug/Valo Health Suspends Development of Diabetic ...
The study's primary objective was to assess the efficacy of OPL-0401 compared to placebo in improving diabetic retinopathy severity score (DRSS) ...
New targets in diabetic retinopathy: addressing limitations ...
This review summarises Sema3A/Nrp1 pathway involvement in DR and RNP and its role as a potential target to treat DR in the context of current treatment options.
OPL-0401 for Diabetic Retinopathy (Spectra Trial)
Trial Overview The study tests OPL-0401's safety and effectiveness in treating diabetic retinopathy compared to a placebo. It's given to people with varying ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.